Federal regulatory oversight of us clinics marketing adipose-derived autologous stem cell interventions: Insights from 3 new FDA draft guidance documents

Mayo Clinic Proceedings

Volumn 90, Issue 5, 2015, Pages 567-571

  Turner, Leigh G ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOSE DERIVED STEM CELL; ADIPOSE TISSUE; ADVERTIZING; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL MANIPULATION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE FACILITY; HUMAN; MARKETING; MEDICAL PRACTICE; MEDICOLEGAL ASPECT; PRACTICE GUIDELINE; PROTOCOL COMPLIANCE; RESPONSIBILITY; REVIEW; STEM CELL RESEARCH; AUTOGRAFT; CYTOLOGY; LEGISLATION AND JURISPRUDENCE; STEM CELL TRANSPLANTATION; UNITED STATES;

ADIPOSE TISSUE; AUTOGRAFTS; HEALTH FACILITIES; HUMANS; MARKETING; PRACTICE GUIDELINES AS TOPIC; STEM CELL TRANSPLANTATION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84929484733     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2015.02.003     Document Type: Short Survey

References (24)

1. E. Dolgin Letter campaign sought to pressure FDA action on stem cell clinics Nat Med 20 8 2014 796 797
2. A. McArdle, K. Senarath-Yapa, and G. Walmsley The role of stem cells in aesthetic surgery: fact or fiction Plast Reconstr Surg 134 2 2014 193 200
3. D. Lau, U. Ogbogu, B. Taylor, T. Stafinski, D. Menon, and T. Caulfield Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine Cell Stem Cell 3 6 2008 591 594
4. D. Sipp Direct-to-consumer stem cell marketing and regulatory responses Stem Cells Transl Med 2 9 2013 638 640
5. L. Freeman State medical board revokes license of stem cell doctor Zannos Grekos Naples Daily News April 5, 2013
6. M. Dobke, J. Bailey, and D. Bhavsar Necrotizing metachronous facial ulcerations after "stem cell face lift." Ann Plast Surg 7 4 2013 392 396
7. Hones v Young and Bioregenesis Institute Corp, U2:12-cv-01951-JCM-PAL (District of Nevada, Las Vegas, 2012).
8. L. DeFrancesco Adult stem cell therapies walk the line Nat Biotechnol 30 8 2012 739 741
9. D. Cyranoski Stem-cell therapy takes off in Texas Nature 483 7387 2012 13 14
10. K. Drabiak-Syed Challenging the FDA's authority to regulate autologous adult stem cells for therapeutic use: Celltex therapeutics' partnership with RNL Bio, substantial medical risks, and the implications of United States v. Regenerative Sciences Health Matrix Clevel 23 2 2013 493 535
11. D. Cyranoski Stem cells in Texas: Cowboy culture Nature 494 7436 2013 166 168
12. J.M. Gimble, B.A. Bunnell, and T. Frazier Adipose-derived stromal/stem cells: a primer Organogenesis 9 1 2013 3 10
13. R.H. Aicher Is the FDA regulating the practice of medicine? Aesthet Surg J 33 3 2013 452 455
14. Human Cells, Tissues, and Cellular and Tissue-Based Products: Establishment Registration and Listing, Final Rule Fed Regist 66 January 19, 2001 5447 5469 http://www.gpo.gov/fdsys/pkg/FR-2001-01-19/pdf/01-1126.pdf Accessed February 2, 2015
15. StemGenex website. http://stemgenex.com. Accessed February 2, 2015.
16. Cell Surgical Network website. http://www.stemcellrevolution.com. Accessed February 2, 2015.
17. Draft Guidance for Industry: Same Surgical Procedure Exception Under 21 CFR 1271.15(b): Questions and Answers Regarding the Scope of the Exception. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/ucm419911.htm. Accessed February 2, 2015.
18. E. Lazarus Letter to Mitchell S. Fuerst, Esq November 2011 Public Health Service, Food and Drug Administration Rockville, MD https://app.box.com/s/v8du7czi944s3xlblr5g Accessed February 2, 2015
19. E. Lazarus Letter December 12, 2011 Public Health Service, Food and Drug Administration Rockville, MD http://www.cosmeticsurg.net/blog/2012/01/11/fda-stem-cells-from-your-own-fat-are-a-drug/ Accessed February 2, 2015
20. M.A. Malarkey Warning letter to Dr. Steven Victor, Chief Executive Officer, IntelliCell Biosciences Inc March 13, 2012 Public Health Service, Food and Drug Administration Rockville, MD http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2012/ucm297245.htm Accessed February 2, 2015
21. M.A. Malarkey Warning letter to Thomas E. Young, MD, Owner and Medical Director, Young Medical Spa April 20, 2012 Public Health Service, Food and Drug Administration Rockville, MD http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2012/ucm301620.htm Accessed February 2, 2015
22. M.A. Malarkey Warning letter to David G. Eller, Chief Executive Officer and President, Celltex Therapeutics Corporation September 24, 2012 Public Health Service, Food and Drug Administration Rockville, MD http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2012/ucm323853.htm Accessed February 2, 2015
23. Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products: Draft Guidance for Industry and Food and Drug Administration Staff December 2014 Food and Drug Administration Rockville, MD http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ucm427692.htm Accessed February 2, 2015
24. Cells Human Tissues, and Cellular and Tissue-Based Products (HCT/Ps) From Adipose Tissue: Regulatory Considerations; Draft Guidance for Industry December 2014 Food and Drug Administration Rockville, MD http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/ucm427795.htm Accessed February 2, 2015